A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Exclusion Criteria

• • History of any clinically important disease or disorder.
• • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of administration of study intervention.
• • Any laboratory values with the following deviations at screening and/or Day 1:
• o Alanine aminotransferase > Upper Limit of Normal (ULN)
• o Aspartate aminotransferase > ULN
• o Total bilirubin > ULN
• o Creatinine > ULN
• o White blood cell count < Lower Limit of Normal (LLN)
• o Hemoglobin < LLN
• o Estimated glomerular filtration rate < 60 mL/min/1.73 m^2
• o Platelets >ULN and/or
• • Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results other than those described above, including participants with platelet or bleeding disorders, known platelet dysfunction disorders.
• • Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or Human Immunodeficiency Virus.
• • Confirmed coronavirus disease 2019 (COVID-19) infection during screening and/or admission by polymerase chain reaction (PCR) test.
• • Abnormal vital signs, after 5 minutes supine rest
• • Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG.
• • Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months.
• • History of alcohol abuse or excessive intake of alcohol
• • History of Drug abuse or positive screen for drug of abuse or cotinine (nicotine) or alcohol.
• • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7503.
• • Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate)
• • Use of any prescribed or non prescribed medication during the 2 weeks prior to the administration of study intervention or longer if the medication has a long half-life.
• • Plasma donation within one month of screening or any blood donation/blood loss more than 500 mL during the 3 months prior to screening.
• • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half lives, whichever is longer) of the administration of study intervention in this study.
• • Any ongoing or recent (ie, during the screening period) minor medical complaints.
• • Previous bone marrow transplant.
• • Non leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.